EcoDrugPlus

4-Hydroxyphenylpyruvate Dioxygenase-Like

Ensembl ID : ENSPNAG00000012797
Gene Symbol: LOC108441909
3 Cross references
204 Possible Orthologues:

40s Ribosomal Protein S25

Ensembl ID : ENSPNAG00000029372
Gene Symbol: LOC108433270
3 Cross references
95 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSPNAG00000013959
Gene Symbol: NT5E
3 Cross references
215 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 1a B

Ensembl ID : ENSPNAG00000015841
Gene Symbol: HTR1AB
1 Cross references
137 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 1b

Ensembl ID : ENSPNAG00000017017
Gene Symbol: HTR1B
1 Cross references
66 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSPNAG00000013992
Gene Symbol: HTR1B
2 Cross references
184 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSPNAG00000024547
Gene Symbol: HTR1F
4 Cross references
140 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSPNAG00000015075
Gene Symbol: HTR1F
4 Cross references
110 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSPNAG00000018815
Gene Symbol: HTR2A
3 Cross references
207 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSPNAG00000007920
Gene Symbol: HTR2A
3 Cross references
206 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a-Like

Ensembl ID : ENSPNAG00000025713
Gene Symbol: LOC108429433
2 Cross references
154 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSPNAG00000009790
Gene Symbol: HTR2B
3 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).